or Try an Advanced Search...

    Technical Analysis for RDHL - Redhill Biopharma Ltd.

    Grade Last Price % Change Price Change
    F 0.48 4.93% 0.02
    RDHL closed up 4.93 percent on Thursday, May 16, 2024, on 1.29 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical RDHL trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Stochastic Sell Signal Bearish 4.93%
    Bollinger Band Squeeze Range Contraction 4.93%
    NR7 Range Contraction 4.93%
    NR7-2 Range Contraction 4.93%
    Narrow Range Bar Range Contraction 4.93%
    Weak + Overbought Other 4.93%
    Older End-of-Day Signals for RDHL ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 6 hours ago
    Rose Above Previous Day's High about 9 hours ago
    Rose Above Upper Bollinger Band about 9 hours ago
    Up 2% about 9 hours ago
    Up 1% about 9 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RDHL Chart by TradingView
    Basic chart:

    Profile

    Redhill Biopharma Ltd. Description

    RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Autoimmune Disease Gastrointestinal Hypertension Antibiotics Heart Failure Dysfunction Inflammatory Bowel Disease Gastroenterology Thin Film Abdominal Pain Crohn's Disease Headache Migraine Nausea Proton Bacteria Gastrointestinal Tract Migraine Headache Treatment Of Hypertension Treatment Of Inflammatory Bowel Disease Helicobacter Migraine Headaches Ventricular Dysfunction

    Is RDHL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 6 RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
    Apr 24 RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
    Apr 8 RedHill GAAP EPS of $0.01, revenue of $6.53M
    Apr 8 RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
    Mar 5 RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
    Feb 20 RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
    Feb 9 RedHill Biopharma files to sell 10.6M ADS for holders
    Jan 26 RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
    Jan 25 Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
    Dec 20 RedHill shares rally 20% on positive data for two antiviral drugs
    See more RDHL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.28
    52 Week Low 0.257
    Average Volume 405,433
    200-Day Moving Average 0.73
    50-Day Moving Average 0.48
    20-Day Moving Average 0.45
    10-Day Moving Average 0.46
    Average True Range 0.03
    RSI (14) 58.16
    ADX 20.43
    +DI 19.87
    -DI 18.76
    Chandelier Exit (Long, 3 ATRs) 0.41
    Chandelier Exit (Short, 3 ATRs) 0.46
    Upper Bollinger Bands 0.48
    Lower Bollinger Band 0.41
    Percent B (%b) 1.05
    BandWidth 14.45
    MACD Line 0.00
    MACD Signal Line -0.01
    MACD Histogram 0.0071
    Fundamentals Value
    Market Cap 14.34 Million
    Num Shares 29.7 Million
    EPS -8.00
    Price-to-Earnings (P/E) Ratio -0.06
    Price-to-Sales 0.48
    Price-to-Book 4.98
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.52
    Resistance 3 (R3) 0.51 0.50 0.51
    Resistance 2 (R2) 0.50 0.49 0.50 0.51
    Resistance 1 (R1) 0.49 0.48 0.49 0.49 0.51
    Pivot Point 0.48 0.48 0.48 0.48 0.48
    Support 1 (S1) 0.47 0.47 0.47 0.47 0.46
    Support 2 (S2) 0.45 0.46 0.45 0.46
    Support 3 (S3) 0.44 0.45 0.45
    Support 4 (S4) 0.45